In this episode of OncTimes Talk, we chat with Tom Hulsey—athlete, author, and prostate cancer survivor—about the life-altering moment he received his diagnosis on his birthday, and how it set him on a path of resilience, advocacy, and renewed purpose. Tom opens up about the emotional toll of staying silent, the power of mindset in healing, and how facing both cancer and heart disease reshaped his outlook on life. He also shares insights from his work with medical research programs and offers powerful advice for men navigating their own health journeys. This is a conversation about vulnerability, strength, and the will to turn pain into purpose.

In this third episode of the OncoExTra® podcast series, host Ruchika Talwar, MD, talks with Christy Russell, MD, Vice President of Medical Affairs at Exact Sciences, about what oncologists can expect when they receive their OncoExTra comprehensive genomic profiling test results, and how they can utilize the report and tap into Exact Sciences' skilled support team to develop a plan of action for their patients.

In this episode of OncTimes Talk, we chat with Sami Mansfield, ACSM-CET, PN1, the founder of Cancer Wellness for Life, an organization dedicated to developing, implementing, and optimizing exercise oncology and lifestyle medicine programs and resources for hospitals, healthcare organizations, pharmaceutical companies, nonprofits, and individuals impacted by cancer.

cancerwellnessforlife.com

In this episode of OncTimes Talk, we chat with Katie Coleman. Diagnosed with an ultra-rare stage IV kidney cancer in 2020, her prognosis had a chance to significantly change after six months. Since then, Katie has since become an Author, founded a non-profit organization, and has become a podcast host—all with the goal of giving back to cancer research.

 

Katiekickscancer.com

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

In this episode, Dr. Ruchika Talwar, a urologic oncologist at Vanderbilt University Medical Center, Dr. Adham Jurdi, a medical oncologist and Senior Director of Oncology at Natera, delve into the groundbreaking world of tumor-informed molecular residual disease testing. Discover how circulating tumor DNA (ctDNA) is revolutionizing cancer detection and treatment, providing real-time insights that surpass traditional imaging methods. Learn about the decades-long journey to perfect this technology, its clinical implications, and the exciting advancements on the horizon.

In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urology at Penn State Health Milton S. Hershey Medical Center, in Hershey, PA.

MacDonald shares her inspiring journey of facing a life-changing diagnosis with strength and resilience. Discover her insights into the healthcare system, the unexpected joys she found, and her advice for others facing similar challenges.

Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients.

 

Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco how the study addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.

At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was in the PROMISE-JAPAN study with 869 Japanese patients.

 

After talking about his group’s new data, lead researcher Koji Hatano, MD, a urologist from Osaka University in Japan, discussed the insights this has given doctors into the metastatic process and potential ways of modifying it.

At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer. Using 2 years of androgen deprivation therapy after radical prostatectomy in high-risk patients with undetectable postoperative PSA did not significantly improve metastasis-free survival. First author François Rozet, MD, a senior surgeon in the Department of Urology at the Institut Mutualiste.

A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance.

 

A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author Ruben Del Castillo, MD, a radiation oncologist from the Sunnybrook Health Sciences Centre in Toronto, Canada, shared the details.